Key Highlights
- Shares of Soleno Therapeutics (SLNO) jumped more than 30% during premarket hours Monday following acquisition reports
- Neurocrine Biosciences (NBIX) is reportedly close to acquiring Soleno in a transaction exceeding $2.5 billion
- Sources suggest the transaction could price SLNO shares in the low-to-mid $50 range
- According to the Financial Times, an agreement may be reached as early as Monday, April 6
- Shares of Neurocrine declined 0.4% in premarket activity following the news
Soleno Therapeutics has faced headwinds throughout 2026 — trading down approximately 14% year to date — but Monday morning brought a dramatic reversal.
Soleno Therapeutics, Inc., SLNO
According to a Financial Times report, Neurocrine Biosciences has entered late-stage negotiations to acquire the rare disease-focused biotech company in a transaction valued at over $2.5 billion. News of the potential deal propelled SLNO shares more than 30% higher in early premarket trading.
The proposed transaction would reportedly price Soleno shares in the low-to-mid $50s. Negotiations are progressing rapidly, with the FT indicating an agreement could materialize as soon as Monday.
Soleno’s primary commercial product is Vykat XR, which the company brought to market last year for the treatment of hyperphagia — a medical condition associated with Prader-Willi syndrome. This condition triggers uncontrollable, relentless hunger that can result in severe complications such as gastric rupture, choking hazards, obesity, and heart disease.
Prader-Willi syndrome represents a rare genetic disorder, affecting approximately one in 15,000 births. Vykat XR stands as the first FDA-approved therapy specifically designed to address the hunger-driven symptoms of this condition.
Wall Street analysts have projected Vykat XR could achieve peak annual revenues approaching $2.3 billion — a figure that appears to have attracted significant interest from Neurocrine.
Neurocrine Expands Into Rare Disease Territory
Neurocrine currently maintains a market capitalization of approximately $13.21 billion. The company’s existing portfolio features Ingrezza, which addresses involuntary movements associated with Huntington’s disease, alongside multiple approved therapies and developmental pipeline assets.
Acquiring Vykat XR would establish Neurocrine’s presence in the rare disease and orphan drug sector, where companies typically enjoy robust pricing capabilities and face minimal competitive pressure.
Shares of Neurocrine slipped 0.4% in premarket trading Monday. This modest decline represents a common market response when an acquiring company announces a major purchase — reflecting investor concerns about the premium being offered.
Putting SLNO’s Performance in Perspective
Despite Monday’s dramatic surge, SLNO had been trading down roughly 14% for 2026 entering this week. The stock had underperformed despite Wall Street’s bullish outlook on Vykat XR’s revenue potential.
According to TipRanks, SLNO carries a Strong Buy rating consensus based on input from 11 analysts. The consensus price target stands at $101.09, with the most optimistic forecast reaching $125.
At the reported acquisition price of low-to-mid $50s per share, the buyout would fall significantly short of analyst price targets — although it still represents a meaningful premium compared to SLNO’s recent trading levels.
The Financial Times report referenced people with knowledge of the negotiations, indicating discussions are advancing smoothly and accelerating toward a potential final agreement.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
